Shareholder Alert: Ademi LLP Investigates Whether Ocuphire Pharma, Inc. Is Breaching Its Duties to Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Ocuphire (Nasdaq: OCUP) for possible breaches of fiduciary duty and other violations of law in its transaction with Opus Genetics.

Click here to learn how to join our investigation or call Guri Ademi toll-free at 866-264-3995. There is no cost or obligation to you.

In the transaction, Ocuphire will issue 5.2 million shares of its common stock and 14.1 thousand shares of its convertible preferred stock to existing stockholders of Opus Genetics. Ocuphire insiders will receive substantial benefits as part of change of control arrangements.

We are investigating the conduct of Ocuphire’s board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

If you own Ocuphire common stock and wish to obtain additional information, please contact Guri Ademi either at [e-mail] or toll-free: 866-264-3995, or here.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights throughout the country. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.